[Hormonal contraception and substitution therapy: the importance of progestogen for cardiovascular diseases].
Epidemiological data have demonstrated, that the progestogen component of oral contraceptives is involved in the development of hypertension, ischaemic heart diseases and stroke. It had been suggested, that atherosclerotic lesions due to the unfavourable effect on lipid metabolism of progestogens with androgenic properties, play a causal role. It has, however, been shown, that there is no development of atherosclerosis despite reduced HDL and elevated LDL, presumably because of the induction of hepatic LDL- and remnant-receptors by the strong effect of ethinyl-oestradiol upon the liver. A series of experimental and clinical findings indicates that vasospasms caused by the vasoconstrictory effect of progestogens are involved in the development of arterial thromboses. In postmenopausal women, the additional administration of progestogens to the oestrogen treatment may trigger ischaemic diseases, particularly in the presence of vascular lesions. Oestrogens exercise a pronounced vasodilatory effect and stabilize the vascular tonus--through changes in the responsiveness of endothelium and smooth muscle cells to vasoactive compounds, through modulation of neurotransmitter release from nerve endings, and through direct blocking of calcium channels. The effects depend essentially on an intact endothelium. By a direct action on the vascular wall, progestogens increase the sensitivity of arteries to vasoconstrictory compounds and reduce blood flow. As aldosterone increases the number of beta-adrenergic receptors in the arterial smooth muscle cells and thus act vasodilatorily, it cannot be excluded, that progestogens with high affinity to the aldosterone receptor and antimineralocorticoid properties, may exert a strong vasoconstrictory effect.(ABSTRACT TRUNCATED AT 400 WORDS)
Kuhl
H
H
Abt. für gynäkol. Endokrinologie, J.W. Goethe-Universität Frankfurt/M.
D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology
D003277:Contraceptives, Oral, Combined; D008055:Lipids; D045167:Progesterone Congeners
Hormonale Kontrazeption und Substitutionstherapie: Die Bedeutung des Gestagens für kardiovaskuläre Erkrankungen.